Search jobs 12-Jul-2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
ASP3772 has also received FDA Breakthrough Therapy Designation
CAMBRIDGE, Mass. & TOKYO (BUSINESS WIRE) Affinivax, Inc. ( Affinivax ) and Astellas Pharma Inc. (“Astellas”) announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting
Streptococcus pneumoniae. Developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) platform technology, ASP3772 is designed to offer both B-cell (antibody) and T-cell immune protection against
Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal modelComplete protection from COVID-19 disease by a single dose skin patch delivery using Vaxxas’ HD-MAP was demonstrated in a lethal challenge of the SARS-.
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Affinivax Appoints Elizabeth Radcliffe as Chief Financial Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.